Results 151 to 160 of about 108,143 (259)

Minimal residual disease in diffuse large B‐cell lymphoma after first‐line therapy: Defining the continuum from metabolic remission to molecular clearance

open access: yesBritish Journal of Haematology, EarlyView.
Summary Response assessment in diffuse large B‐cell lymphoma (DLBCL) has traditionally relied on anatomical and metabolic imaging, with fluorodeoxyglucose positron emission tomography (FDG‐PET)–defined complete metabolic remission representing the principal end‐point of first‐line therapy. However, growing evidence indicates that metabolic control does
Santino Caserta   +12 more
wiley   +1 more source

Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma. [PDF]

open access: yesCells
Maher N   +6 more
europepmc   +1 more source

Response‐adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Secondary central nervous system lymphoma (SCNSL) remains a rare but challenging manifestation of aggressive lymphomas, with limited prospective data to guide treatment decisions in the modern therapeutic era. We conducted a multicentre retrospective cohort study of 105 consecutively treated adult patients diagnosed with SCNSL between 2016 and ...
Farina Eigendorff   +10 more
wiley   +1 more source

Real‐world comparison of peripheral neuropathy and treatment delivery between Pola‐R‐CHP and R‐CHOP in DLBCL

open access: yes
British Journal of Haematology, EarlyView.
Nobuhiko Nakamura   +11 more
wiley   +1 more source

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study

open access: yesBritish Journal of Haematology, EarlyView.
Real‐world nationwide data in B‐cell malignancies reveal a markedly increased 1‐year incidence of hospitalized atrial fibrillation with ibrutinib compared with second‐generation Bruton's tyrosine kinase inhibitors and venetoclax, arguing for closer cardiac surveillance.
Yoann Zelmat   +5 more
wiley   +1 more source

Diffuse Large B-Cell Lymphoma With Pulmonary and Gastric Involvement Mimicking Nontuberculous Mycobacterial Lung Disease. [PDF]

open access: yesRespirol Case Rep
Masuda K   +13 more
europepmc   +1 more source

Effects of chronic lymphocytic leukaemia (CLL)‐directed therapy on diffuse large B‐cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) type Richter transformation (DLBCL‐RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL‐RT with or without previous CLL‐directed therapy compared to dnDLBCL between 2002 and 2022.
Andreas Katsimigas   +9 more
wiley   +1 more source

Plasmacytic markers as immunotherapeutic targets for primary CD20‐negative aggressive B‐cell lymphomas

open access: yes
British Journal of Haematology, EarlyView.
Frank Neumann   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy